ClinicalTrials.gg
CompletedNCT00696241Updated Jul 29, 2011Results posted

Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension

A Phase 3 interventional study of Azilsartan medoxomil and olmesartan and Azilsartan medoxomil and olmesartan in Hypertension, sponsored by Takeda. Completed at 85 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-07-29.

Primary conditionEssential HypertensionRegistry: HypertensionReclassifiedWhy we changed it
Registry
Hypertension — the first condition term the registry derived for this study.
ClinicalTrials.gg
Essential Hypertension
Why
  1. The study's title name Essential Hypertension, a narrower term within Hypertension.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,275
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing azilsartan medoxomil in Essential Hypertension — none open to participants now, none under way, none of them phase 3. azilsartan medoxomil · Essential Hypertension.

Enrollment
2nd of 11
1,275 · median 837
Started
2007
with 2 others
Phase 3
10 of 11
none open now
Registered
1st of 11
by date
Lead sponsor
11 of 11
Takeda

Among the 11 studies testing azilsartan medoxomil in Essential Hypertension, this one is the 2nd largest by enrollment, is one of 3 that started in 2007, is one of 10 in phase 3, and was the 1st registered.

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

None of the 11 studies testing azilsartan medoxomil in Essential Hypertension is open now. The open studies under Essential Hypertension, anywhere →

About azilsartan medoxomil

azilsartan medoxomil: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing azilsartan medoxomil in Essential Hypertension as a file.
02

Study summary

The purpose of this study is to determine the safety and efficacy of azilsartan medoxomil, once daily (QD), compared to placebo and olmesartan in participants with essential hypertension.

Read the detailed description

Hypertension affects approximately 50 million individuals in the United States. As the population ages, the prevalence of hypertension will continue to increase if broad and effective preventive measures are not implemented. According to the World Health Organization, hypertension is the most common attributable cause of preventable death in developed nations, as uncontrolled hypertension greatly increases the risk of cardiovascular disease, cerebrovascular disease, and renal failure. Despite the availability of antihypertensive treatments, hypertension remains inadequately controlled; only about one-third of patients continue to maintain control successfully.

TAK-491 (azilsartan medoxomil) is an angiotensin II receptor blocker and this study is being conducted to evaluate the efficacy and safety of oral azilsartan medoxomil compared to placebo and olmesartan in subjects with essential hypertension.

Individuals who want to participate in this study will be required to provide written informed consent. Study participation is anticipated to be about 11 weeks. Multiple procedures will occur at each visit which may include fasting, blood collection, urine collection, vital signs including sitting blood pressure and pulse, body height and weight, physical examinations and electrocardiograms. Outside of the study center, participants will be required to wear an ambulatory blood pressure monitoring device at 24 hour intervals.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Essential Hypertension
  • Cardiovascular Disease
  • High Blood Pressure
  • Drug Therapy
04

In context

Essential Hypertension Reclassified

480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.

This study's enrollment of 1,275 is above the median of 144 across 407 interventional studies indexed under Essential Hypertension.

Browse Essential Hypertension studies →

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Compared within Essential Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has essential hypertension (defined as sitting trough clinic systolic blood pressure between 150 and 180 mm Hg, inclusive at Day minus 1) and 24-hour mean systolic blood pressure greater than or equal to 130 mm Hg and less than or equal to 170 mm Hg at Day 1).
  2. Females of who are sexually active must agree to use adequate , and can neither be pregnant nor lactating from Screening throughout the duration of the study.
  3. Clinical laboratory evaluations (including clinical chemistry, hematology, and complete urinalysis) within the reference range for the testing laboratory or the results are deemed not for inclusion into this study by the investigator.
  4. The subject is willing to discontinue current antihypertensive medications at the Screening Day minus 21 visit. If the subject is on amlodipine prior to screening, the subject is willing to discontinue this medication at Screening Day minus 28.

Exclusion criteria

Exclusion Criteria

  1. Sitting trough clinic diastolic blood pressure greater than 114 mm Hg at Day minus 1.
  2. Baseline 24-hour ambulatory blood pressure monitor reading of insufficient quality.
  3. History of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or .
  4. cardiac conduction defects (eg, third degree atrioventricular block, left bundle branch block, sick sinus syndrome, atrial fibrillation or atrial flutter).
  5. Hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease.
  6. Secondary hypertension of any etiology.
  7. Is noncompliant (less than 70% or greater than 130%) with study medication during Placebo Run-In Period.
  8. Severe renal dysfunction or disease (based on calculated less than 30 mL/min/1.73 m2) at Screening.
  9. Known or suspected unilateral or bilateral renal artery stenosis.
  10. History of drug abuse (defined as illicit drug use) or a history of alcohol abuse (defined as regular or daily consumption of more than 2 alcoholic drinks per day) within the past 2 years.
  11. History of cancer that has not been in remission for at least 5 years prior to the first dose of study drug. (This criterion does not apply to those subjects with basal cell or stage I squamous cell carcinoma of the skin).
  12. Type 1 or poorly controlled type 2 diabetes mellitus (glycosylated greater than 8.0%) at Screening.
  13. level greater than 2.5 times the , active liver disease, or jaundice at Screening.
  14. Hyperkalemia (defined as serum potassium greater than the upper limit of normal per the central laboratory) at Screening.
  15. Upper arm circumference less than 24 cm or greater than 42 cm.
  16. Works night (3rd) shift (defined as 11 PM to 7 AM).
  17. Currently participating in another study or has participated in an investigational study within 30 days prior to Screening.
  18. Any other serious disease or condition at Screening (or Randomization) that would compromise subject safety, might affect , or make it difficult to successfully manage and follow the subject according to the protocol.
  19. Randomized in a previous azilsartan medoxomil study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,275 participants (actual)

Study arms

  • Experimental
    Azilsartan Medoxomil 20 mg QD

    Drug: Azilsartan medoxomil and olmesartan

  • Experimental
    Azilsartan Medoxomil 40 mg QD

    Drug: Azilsartan medoxomil and olmesartan

  • Experimental
    Azilsartan Medoxomil 80 mg QD

    Drug: Azilsartan medoxomil and olmesartan

  • Active comparator
    Olmesartan 40 mg QD

    Drug: Olmesartan

  • Placebo comparator
    Placebo QD

    Drug: Placebo

Interventions

  • DrugAzilsartan medoxomil and olmesartan

    Drug pages: Azilsartan medoxomil · Olmesartan

    Azilsartan medoxomil 20 mg, tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.

    Also known as: TAK-491, Edarbi

  • DrugAzilsartan medoxomil and olmesartan

    Drug pages: Azilsartan medoxomil · Olmesartan

    Azilsartan medoxomil 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.

    Also known as: TAK-491, Edarbi

  • DrugAzilsartan medoxomil and olmesartan

    Drug pages: Azilsartan medoxomil · Olmesartan

    Azilsartan medoxomil 80 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.

    Also known as: TAK-491, Edarbi

  • Olmesartan 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily for up to 6 weeks.

    Also known as: Benicar®

  • DrugPlacebo

    Azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and olmesartan 40 mg placebo- matching tablets, orally, once daily for up to 6 weeks.

07

What researchers measure

Primary outcomes

  1. Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in 24-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

    Time frame: Baseline and Week 6.

Secondary outcomes

  1. Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure

    The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline.

    Time frame: Baseline and Week 6.

  2. Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in 24-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

    Time frame: Baseline and Week 6.

  3. Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure

    The change in mean trough clinic sitting diastolic blood pressure measured at final visit or week 6 relative to baseline.

    Time frame: Baseline and Week 6.

  4. Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

    Time frame: Baseline and Week 6.

  5. Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

    Time frame: Baseline and Week 6.

  6. Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

    Time frame: Baseline and Week 6.

  7. Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

    Time frame: Baseline and Week 6.

  8. Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring

    The change in the 12-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

    Time frame: Baseline and Week 6.

  9. Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring

    The change in the 12-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

    Time frame: Baseline and Week 6.

  10. Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in trough mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.

    Time frame: Baseline and Week 6.

  11. Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in trough mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.

    Time frame: Baseline and Week 6.

  12. Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg

    Percentage of participants who achieve a clinic systolic blood pressure response measured at week 6, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.

    Time frame: Baseline and Week 6.

  13. Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg

    Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.

    Time frame: Baseline and Week 6.

  14. Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response

    Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the 3 sitting blood pressure measurements.

    Time frame: Baseline and Week 6.

08

Results

Posted Apr 19, 2011

Participant flow

Participants enrolled at 147 investigative sites in Argentina, Mexico, Peru and the United States from 25 June 2007 to 08 October 2008.

Participant flow — Overall Study
MilestoneAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 40 mg QDPlacebo QD
Started283283285282142
Completed259261261268130
Not completed2422241412
Withdrew: Adverse event113645
Withdrew: Protocol violation11203
Withdrew: Lost to follow-up14120
Withdrew: Withdrawal by subject48610
Withdrew: Lack of efficacy15453
Withdrew: Other61521

Outcome measures

PrimaryChange From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in 24-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 40 mg QDPlacebo QD
Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-12.15 ± 0.709-13.48 ± 0.704-14.62 ± 0.706-12.56 ± 0.696-1.40 ± 1.004
Statistical analysis
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented. Overall 0.05 level of significance for multiple comparisons controlled using stepwise testing procedure.) · Mean difference (final values): -10.75 · 95% CI -13.17 to -8.34
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented. Overall 0.05 level of significance for multiple comparisons controlled using stepwise testing procedure.) · Mean difference (final values): -12.08 · 95% CI -14.48 to -9.67
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented. Overall 0.05 level of significance for multiple comparisons controlled using stepwise testing procedure.) · Mean difference (final values): -13.21 · 95% CI -15.62 to -10.81
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.687 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented. Overall 0.05 level of significance for multiple comparisons controlled using stepwise testing procedure.) · Mean difference (final values): 0.40 · 95% CI -1.55 to 2.35
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.352 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented. Overall 0.05 level of significance for multiple comparisons controlled using stepwise testing procedure.) · Mean difference (final values): -0.92 · 95% CI -2.87 to 1.02
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.038 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented. Overall 0.05 level of significance for multiple comparisons controlled using stepwise testing procedure.) · Mean difference (final values): -2.06 · 95% CI -4.00 to -0.12
SecondaryChange From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure

The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure
mmHgAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 40 mg QDPlacebo QD
Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure-14.28 ± 0.956-14.47 ± 0.952-17.58 ± 0.947-14.87 ± 0.945-2.06 ± 1.337
Statistical analysis
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented. Overall 0.05 level of significance for multiple comparisons controlled using stepwise testing procedure.) · Mean difference (final values): -12.23 · 95% CI -15.45 to -9.00
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented. Overall 0.05 level of significance for multiple comparisons controlled using stepwise testing procedure.) · Mean difference (final values): -12.42 · 95% CI -15.64 to -9.20
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented. Overall 0.05 level of significance for multiple comparisons controlled using stepwise testing procedure.) · Mean difference (final values): -15.53 · 95% CI -18.74 to -12.31
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.662 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented. Overall 0.05 level of significance for multiple comparisons controlled using stepwise testing procedure.) · Mean difference (final values): 0.59 · 95% CI -2.05 to 3.22
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.768 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented. Overall 0.05 level of significance for multiple comparisons controlled using stepwise testing procedure.) · Mean difference (final values): 0.40 · 95% CI -2.24 to 3.03
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.043 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented. Overall 0.05 level of significance for multiple comparisons controlled using stepwise testing procedure.) · Mean difference (final values): -2.71 · 95% CI -5.34 to -0.09
SecondaryChange From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in 24-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 40 mg QDPlacebo QD
Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-7.47 ± 0.458-8.38 ± 0.455-8.61 ± 0.456-7.74 ± 0.449-0.69 ± 0.649
Statistical analysis
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = <0.001 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -6.78 · 95% CI -8.34 to -5.22
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = <0.001 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -7.68 · 95% CI -9.24 to -6.13
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = <0.001 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -7.92 · 95% CI -9.47 to -6.36
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.679 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): 0.27 · 95% CI -0.99 to 1.52
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.319 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -0.64 · 95% CI -1.89 to 0.62
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.172 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -0.87 · 95% CI -2.13 to 0.38
SecondaryChange From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure

The change in mean trough clinic sitting diastolic blood pressure measured at final visit or week 6 relative to baseline.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure
mmHgAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 40 mg QDPlacebo QD
Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure-6.82 ± 0.535-6.86 ± 0.533-8.42 ± 0.530-6.91 ± 0.5290.21 ± 0.749
Statistical analysis
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = <0.001 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -7.02 · 95% CI -8.83 to -5.22
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = <0.001 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -7.07 · 95% CI -8.87 to -5.27
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = <0.001 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -8.62 · 95% CI -10.42 to -6.82
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.908 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): 0.09 · 95% CI -1.39 to 1.56
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.956 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): 0.04 · 95% CI -1.43 to 1.52
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.044 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -1.51 · 95% CI -2.98 to -0.04
SecondaryChange From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 40 mg QDPlacebo QD
Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-12.57 ± 0.751-13.75 ± 0.746-14.96 ± 0.747-12.73 ± 0.737-1.54 ± 1.064
Statistical analysis
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = <0.001 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -11.03 · 95% CI -13.59 to -8.48
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = <0.001 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -12.20 · 95% CI -14.75 to -9.65
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = <0.001 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -13.41 · 95% CI -15.97 to -10.86
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.879 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): 0.16 · 95% CI -1.90 to 2.22
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.334 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -1.01 · 95% CI -3.07 to 1.04
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.034 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -2.22 · 95% CI -4.28 to -0.16
SecondaryChange From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 40 mg QDPlacebo QD
Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-7.71 ± 0.490-8.43 ± 0.487-8.87 ± 0.488-7.82 ± 0.481-0.59 ± 0.695
Statistical analysis
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = <0.001 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -7.12 · 95% CI -8.79 to -5.45
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = <0.001 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -7.84 · 95% CI -9.51 to -6.18
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = <0.001 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -8.28 · 95% CI -9.94 to -6.61
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.877 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): 0.11 · 95% CI -1.24 to 1.45
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.369 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -0.62 · 95% CI -1.96 to 0.73
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.126 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -1.05 · 95% CI -2.39 to 0.30
SecondaryChange From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 40 mg QDPlacebo QD
Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-11.10 ± 0.781-12.39 ± 0.775-13.35 ± 0.777-12.13 ± 0.766-0.97 ± 1.105
Statistical analysis
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = <0.001 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -10.13 · 95% CI -12.79 to -7.48
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = <0.001 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -11.43 · 95% CI -14.07 to -8.78
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = <0.001 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -12.38 · 95% CI -15.03 to -9.73
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.346 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): 1.03 · 95% CI -1.12 to 3.18
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.811 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -0.26 · 95% CI -2.40 to 1.88
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.267 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -1.21 · 95% CI -3.35 to 0.93
SecondaryChange From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 40 mg QDPlacebo QD
Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-6.98 ± 0.533-7.90 ± 0.530-7.79 ± 0.531-7.62 ± 0.523-0.96 ± 0.755
Statistical analysis
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = <0.001 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -6.03 · 95% CI -7.84 to -4.21
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = <0.001 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -6.94 · 95% CI -8.75 to -5.13
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = <0.001 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -6.84 · 95% CI -8.65 to -5.03
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.394 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): 0.64 · 95% CI -0.83 to 2.10
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.712 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -0.27 · 95% CI -1.74 to 1.19
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.818 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -0.17 · 95% CI -1.63 to 1.29
SecondaryChange From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring

The change in the 12-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
mmHgAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 40 mg QDPlacebo QD
Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring-12.72 ± 0.795-14.05 ± 0.790-15.18 ± 0.791-13.07 ± 0.780-1.36 ± 1.126
Statistical analysis
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = <0.001 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -11.35 · 95% CI -14.05 to -8.64
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = <0.001 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -12.68 · 95% CI -15.38 to -9.98
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = <0.001 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -13.81 · 95% CI -16.51 to -11.11
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.750 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): 0.35 · 95% CI -1.83 to 2.54
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.378 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -0.98 · 95% CI -3.16 to 1.20
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.059 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -2.10 · 95% CI -4.28 to 0.08
SecondaryChange From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring

The change in the 12-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
mmHgAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 40 mg QDPlacebo QD
Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring-7.72 ± 0.519-8.63 ± 0.516-8.88 ± 0.517-7.86 ± 0.510-0.47 ± 0.736
Statistical analysis
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = <0.001 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -7.25 · 95% CI -9.02 to -5.48
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = <0.001 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -8.16 · 95% CI -9.92 to -6.40
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = <0.001 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -8.41 · 95% CI -10.17 to -6.65
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.845 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): 0.14 · 95% CI -1.29 to 1.57
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.290 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -0.77 · 95% CI -2.19 to 0.65
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.161 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -1.02 · 95% CI -2.44 to 0.41
SecondaryChange From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in trough mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 40 mg QDPlacebo QD
Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-12.15 ± 0.864-12.39 ± 0.858-13.42 ± 0.862-11.10 ± 0.848-1.21 ± 1.224
Statistical analysis
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = <0.001 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -10.94 · 95% CI -13.88 to -8.00
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = <0.001 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -11.18 · 95% CI -14.11 to -8.24
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = <0.001 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -12.21 · 95% CI -15.15 to -9.28
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.385 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -1.05 · 95% CI -3.43 to 1.33
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.285 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -1.29 · 95% CI -3.66 to 1.08
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.054 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -2.33 · 95% CI -4.70 to 0.04
SecondaryChange From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in trough mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 40 mg QDPlacebo QD
Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-7.96 ± 0.614-7.93 ± 0.610-8.68 ± 0.612-7.56 ± 0.603-1.12 ± 0.870
Statistical analysis
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = <0.001 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -6.84 · 95% CI -8.93 to -4.75
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = <0.001 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -6.80 · 95% CI -8.89 to -4.72
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = <0.001 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -7.55 · 95% CI -9.64 to -5.47
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.642 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -0.40 · 95% CI -2.09 to 1.29
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.672 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -0.36 · 95% CI -2.05 to 1.32
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.196 (P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -1.11 · 95% CI -2.80 to 0.57
SecondaryPercentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg

Percentage of participants who achieve a clinic systolic blood pressure response measured at week 6, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.

Time frame:
Baseline and Week 6.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg
percentage of participantsAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 40 mg QDPlacebo QD
Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg47.850.456.653.217.1
Statistical analysis
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · Regression, Logistic · p = <0.001 (P-value for response criteria for systolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 4.48 · 95% CI 2.71 to 7.39
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · Regression, Logistic · p = <0.001 (P-value for response criteria for systolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 4.97 · 95% CI 3.01 to 8.20
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · Regression, Logistic · p = <0.001 (P-value for response criteria for systolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 6.53 · 95% CI 3.95 to 10.79
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 40 mg QD · Regression, Logistic · p = 0.173 (P-value for response criteria for systolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 0.79 · 95% CI 0.57 to 1.11
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 40 mg QD · Regression, Logistic · p = 0.449 (P-value for response criteria for systolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 0.88 · 95% CI 0.63 to 1.23
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 40 mg QD · Regression, Logistic · p = 0.402 (P-value for response criteria for systolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 1.15 · 95% CI 0.83 to 1.62
SecondaryPercentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg

Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.

Time frame:
Baseline and Week 6.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg
percentage of participantsAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 40 mg QDPlacebo QD
Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg67.571.073.573.947.9
Statistical analysis
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · Regression, Logistic · p = <0.001 (P-value for response criteria for diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic diastolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 2.86 · 95% CI 1.82 to 4.48
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · Regression, Logistic · p = <0.001 (P-value for response criteria for diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic diastolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 3.39 · 95% CI 2.15 to 5.35
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · Regression, Logistic · p = <0.001 (P-value for response criteria for diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic diastolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 3.81 · 95% CI 2.41 to 6.02
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 40 mg QD · Regression, Logistic · p = 0.177 (P-value for response criteria for diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic diastolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 0.76 · 95% CI 0.52 to 1.13
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 40 mg QD · Regression, Logistic · p = 0.628 (P-value for response criteria for diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic diastolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 0.91 · 95% CI 0.61 to 1.35
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 40 mg QD · Regression, Logistic · p = 0.928 (P-value for response criteria for diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic diastolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 1.02 · 95% CI 0.68 to 1.52
SecondaryPercentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response

Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the 3 sitting blood pressure measurements.

Time frame:
Baseline and Week 6.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response
percentage of participantsAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 40 mg QDPlacebo QD
Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response42.745.352.047.514.3
Statistical analysis
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · Regression, Logistic · p = <0.001 (P-value for joint response criteria for systolic blood pressure and diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 4.53 · 95% CI 2.66 to 7.72
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · Regression, Logistic · p = <0.001 (P-value for joint response criteria for systolic blood pressure and diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 5.04 · 95% CI 2.96 to 8.58
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · Regression, Logistic · p = <0.001 (P-value for joint response criteria for systolic blood pressure and diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 6.75 · 95% CI 3.96 to 11.48
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 40 mg QD · Regression, Logistic · p = 0.217 (P-value for joint response criteria for systolic blood pressure and diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 0.81 · 95% CI 0.58 to 1.13
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 40 mg QD · Regression, Logistic · p = 0.537 (P-value for joint response criteria for systolic blood pressure and diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 0.90 · 95% CI 0.64 to 1.26
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 40 mg QD · Regression, Logistic · p = 0.276 (P-value for joint response criteria for systolic blood pressure and diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 1.20 · 95% CI 0.86 to 1.68

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug and no more than 14 days (or 30 days for a serious adverse event) after the last dose of double-blind study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Azilsartan Medoxomil 20 mg QD—8/283 (2.8%)23/283 (8.1%)
Azilsartan Medoxomil 40 mg QD—0/281 (0%)19/281 (6.8%)
Azilsartan Medoxomil 80 mg QD—1/284 (0.4%)32/284 (11.3%)
Olmesartan 40 mg QD—2/282 (0.7%)18/282 (6.4%)
Placebo QD—3/142 (2.1%)13/142 (9.2%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 40 mg QDPlacebo QD
Coronary artery diseaseCardiac disorders0/2830/2810/2840/2821/142
Chest painGeneral disorders0/2830/2810/2840/2821/142
IschaemiaVascular disorders0/2830/2810/2840/2821/142
Inguinal herniaGastrointestinal disorders0/2830/2810/2841/2820/142
Cholecystitis chronicHepatobiliary disorders0/2830/2810/2841/2820/142
Atrial fibrillationCardiac disorders1/2830/2810/2840/2820/142
Myocardial infarctionCardiac disorders1/2830/2810/2840/2820/142
CellulitisInfections and infestations1/2830/2810/2840/2820/142
Lower respiratory tract infectionInfections and infestations1/2830/2810/2840/2820/142
PneumoniaInfections and infestations1/2830/2810/2840/2820/142
Most frequent other events
Most frequent other events
EventAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 40 mg QDPlacebo QD
HeadacheNervous system disorders13/2839/28116/2849/28210/142
DyslipidemiaMetabolism and nutrition disorders10/28311/28116/28410/2823/142

Baseline characteristics

Age Categorical
Age Categorical(participants)Azilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 40 mg QDPlacebo QDTotal
<45 years3229373211141
Between 45 and 64 years17318716115384758
≥65 years7867879747376
Sex: Female, Male
Sex: Female, Male(Participants)Azilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 40 mg QDPlacebo QDTotal
Female15014113614266635
Male13314214914076640
09

Study locations

85 sites
  • Birmingham, Alabama, United States
  • Huntsville, Alabama, United States
  • Mesa, Arizona, United States
  • Phoenix, Arizona, United States
  • Tempe, Arizona, United States
  • Little Rock, Arkansas, United States
  • Tempe, Arkansas, United States
  • Beverly Hills, California, United States
  • Carmichael, California, United States
  • Fountain Valley, California, United States
  • Long Beach, California, United States
  • Los Gatos, California, United States
  • Orangevale, California, United States
  • Sacramento, California, United States
  • Santa Ana, California, United States
  • Spring Valley, California, United States
  • Tustin, California, United States
  • Westlake Village, California, United States
  • Colorado Springs, Colorado, United States
  • Farmington, Connecticut, United States
  • Hollywood, Florida, United States
  • Jacksonville, Florida, United States
  • Jupiter, Florida, United States
  • Melbourne, Florida, United States
  • Miami, Florida, United States
  • Naples, Florida, United States
  • Ocala, Florida, United States
  • Pembroke Pines, Florida, United States
  • Sarasota, Florida, United States
  • St. Petersburg, Florida, United States
  • Augusta, Georgia, United States
  • Lawrenceville, Georgia, United States
  • Chicago, Illinois, United States
  • Melrose Park, Illinois, United States
  • Naperville, Illinois, United States
  • Round Lake Beach, Illinois, United States
  • Valparaiso, Indiana, United States
  • Wichita, Kansas, United States
  • Erlanger, Kentucky, United States
  • Lexington, Kentucky, United States
  • Auburn, Maine, United States
  • West Yarmouth, Massachusetts, United States
  • Benzonia, Michigan, United States
  • Chelsea, Michigan, United States
  • Omaha, Nebraska, United States
  • Trenton, New Jersey, United States
  • Wildwood Crest, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Brooklyn, New York, United States
  • Orangevale, New York, United States
  • Rochester, New York, United States
  • Burlington, North Carolina, United States
  • Charlotte, North Carolina, United States
  • Raleigh, North Carolina, United States
  • Salisbury, North Carolina, United States
  • Statesville, North Carolina, United States
  • Wilmington, North Carolina, United States
  • Winston-Salem, North Carolina, United States
  • Kettering, Ohio, United States
  • Lyndhurst, Ohio, United States
  • Marion, Ohio, United States
  • Norman, Oklahoma, United States
  • Oklahoma City, Oklahoma, United States
  • Altoona, Pennsylvania, United States
  • Reading, Pennsylvania, United States
  • Mt. Pleasant, South Carolina, United States
  • Simpsonville, South Carolina, United States
  • Taylors, South Carolina, United States
  • Nashville, Tennessee, United States
  • New Tazewell, Tennessee, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • Lake Jackson, Texas, United States
  • North Richland Hills, Texas, United States
  • San Antonio, Texas, United States
  • Draper, Utah, United States
  • Burke, Virginia, United States
  • Norfolk, Virginia, United States
  • Tacoma, Washington, United States
  • Madison, Wisconsin, United States
  • Provincia de Buenos Aires, Argentina
  • Provincia de Cordoba, Argentina
  • Aguascalientes,, Mexico
  • Mexico DF, Mexico
  • San Luis Potosi, Mexico
10

References and documents

Publications

  • White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, Kupfer S. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011 Mar;57(3):413-20. doi: 10.1161/HYPERTENSIONAHA.110.163402. Epub 2011 Jan 31. PubMed 21282560 ↗
  • Bakris GL, Sica D, Weber M, White WB, Roberts A, Perez A, Cao C, Kupfer S. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich). 2011 Feb;13(2):81-8. doi: 10.1111/j.1751-7176.2010.00425.x. PubMed 21272195 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2008
First posted
Jun 12, 2008
Start
Jun 2007
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
Apr 19, 2011
Last update
Jul 29, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00696241
Lead sponsor
Takeda
First posted
Jun 12, 2008
Start date
Jun 2007
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Apr 19, 2011
Last update
Jul 29, 2011

Study contacts

VP Clinical Science Strategy
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azilsartan medoxomil · Olmesartan

Start the discussion